• Events
  • Expert meeting: The Foundation convenes high-level meeting on...
Expert meeting - Event date: 05 Sep 2018

The Foundation convenes high-level meeting on access to medicine and combatting AMR in Mumbai

On 5 September, the Foundation will convene a high-level meeting on access to medicine and combatting AMR in Mumbai. The goal of the event is to share best practices and encourage mutual learning through an open discussion about improving access and pharmaceutical company action on AMR. The event will bring together leaders from the pharmaceutical industry and experts in access to medicine to share successful approaches for appropriately reaching the 2 billion people worldwide who cannot access the medicine they need.

Following its discussions with government representatives and Indian pharmaceutical companies that are already actively addressing antimicrobial resistance (AMR), held in India in March, the Foundation organises this meeting to share best practices and encourage mutual learning through an open discussion about improving access and pharmaceutical company action on AMR.

The event will be opened with a keynote speech by Soumya Swaminathan, Deputy Director-General for Programmes at WHO, followed by a presentation and key insights from the Access to Medicine Foundation. The event will continue with a leadership panel discussion on access to medicine, moderated by Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation. Dilip Shah, Secretary General of the Indian Pharmaceutical Alliance, and Kanchana T.K., Director General of the Organization of Pharmaceutical Producers of India, will also speak on the role of pharmaceutical companies in improving access to medicine. The afternoon sessions include expert discussions about R&D, appropriate access to medicine and the responsible, sustainable manufacturing of antibiotics. Throughout the day, the speakers will exchange ideas in an open forum on how global pharmaceutical companies with a strong presence in India can expand good practice.


Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.